Farther Finance Advisors LLC Has $2.44 Million Stock Position in IQVIA Holdings Inc. $IQV

Farther Finance Advisors LLC increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 899.1% during the 4th quarter, HoldingsChannel reports. The fund owned 10,820 shares of the medical research company’s stock after purchasing an additional 9,737 shares during the quarter. Farther Finance Advisors LLC’s holdings in IQVIA were worth $2,439,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of IQV. Ameliora Wealth Management Ltd. bought a new stake in IQVIA in the fourth quarter valued at approximately $25,000. Physician Wealth Advisors Inc. lifted its holdings in IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after acquiring an additional 134 shares in the last quarter. Westside Investment Management Inc. grew its stake in IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 101 shares during the period. Measured Wealth Private Client Group LLC bought a new stake in shares of IQVIA in the third quarter worth about $30,000. Finally, Atlantic Union Bankshares Corp bought a new position in shares of IQVIA during the 3rd quarter valued at about $36,000. Institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on IQV. Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective on the stock in a research report on Friday, March 6th. Truist Financial dropped their price target on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research note on Thursday, February 19th. UBS Group cut their price target on IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a report on Friday, February 6th. BMO Capital Markets set a $250.00 price objective on IQVIA in a report on Friday, February 6th. Finally, Citigroup cut their target price on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, IQVIA has a consensus rating of “Buy” and an average target price of $226.63.

IQVIA Price Performance

Shares of NYSE IQV opened at $176.48 on Friday. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. The business has a 50-day moving average of $170.75 and a 200-day moving average of $203.91. The stock has a market capitalization of $29.95 billion, a price-to-earnings ratio of 22.45, a PEG ratio of 1.66 and a beta of 1.39. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.02. The business had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.IQVIA’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.